Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce important new data from our ongoing ACCENT clinical trial in pancreatic cancer. The trial is investigating the Company’s best-in-class FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies gemcitabine and Abraxane. Fifteen (15) confirmed partial responses (PRs) have…
Greenvale Energy (GRV:AU) has announced Multiple Uranium Anomalies Identified at Key NT Projects Download the PDF here. This post…
Eric Nuttall, partner and senior portfolio manager at Ninepoint Partners, shares his outlook for oil and natural gas, honing…
Tolu Minerals Limited (“Tolu”) is pleased to announce the granting of its Ipi River tenement EL 2780 (Figure 1)…
Saga Metals Corp. (‘SAGA’ or the ‘Company’) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H) a North American exploration company specializing…
Rare earths are important for many of today’s technologies and tomorrow’s carbon-free economy. Investors may not be very familiar…
Electric Royalties Ltd. (TSXV:ELEC)(OTCQB:ELECF) (‘Electric Royalties’ or the ‘Company’) notes that the recent export restrictions imposed by China on…
Endolith has reported a major advance in copper extraction as it pushes the frontiers of microbial science. In collaboration…
Just in time for Canada Crypto Week, Robinhood Markets (NASDAQ:HOOD) has announced a definitive agreement to acquire Canadian digital…